---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-108980"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2026-09-18T21:16:51+00:00"
generated_at: "2026-09-18T21:18:14.372403+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Shareholders approve Zymeworks merger; closing expected Sept 23, 2026

## Summary
- Merger Proposal approved: 40,993,370 for, 8,671 against, 84,733 abstentions (>2/3 required).
- Advisory merger-related compensation proposal also approved (40,587,829 for, 470,381 against).
- Merger expected to close on or about Sept 23, 2026; Theravance to become wholly owned subsidiary of Zymeworks.
- CVR Agreement contingent consideration remains subject to future payment conditions.
- Quorum of 79.14% (41,086,774 shares) present; adjournment proposal not needed.

## SEC filing metadata
- accession: 0001104659-26-108980
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2026-09-18T21:16:51+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465926108980/0001104659-26-108980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465926108980/tm2625672d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-108980
- JSON: https://secwatch.observer/filing/0001104659-26-108980.json
- Plain text: https://secwatch.observer/filing/0001104659-26-108980.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.